Use of agonists of the dectin-1/Syk pathay as adjuvant in vivo

We have used agonists of the dectin-1/Syk pathway as adjuvants in vivo to induce CD8+ T cell responses and have data available on this. In summary, we have shown that this can result in CTL capable of destroying tumours.

• cell type
• T cell

• molecule type
• CD8

created over 15 years ago (10 December 2009)    last modified over 12 years ago (17 December 2012)   [ RDF ]   [ RelFinder ]